Search
Bausch Health Companies Inc
BHCAdd to Watchlist
5.425USD
+0.135+2.55%
Market hours （ET）Quotes delayed by 15 min
2.03BMarket Cap
LossP/E TTM
More Details of Bausch Health Companies Inc Company
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
Bausch Health Companies Inc Info
Ticker SymbolBHC
Company nameBausch Health Companies Inc
IPO dateSep 20, 1994
CEOAppio (Thomas J)
Number of employees20700
Security typeOrdinary Share
Fiscal year-endSep 20
Address2150 St. Elzear Blvd. West
CityLAVAL
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryCanada
Postal codeH7L 4A8
Phone18003611448
Websitehttps://www.bauschhealth.com/
Ticker SymbolBHC
IPO dateSep 20, 1994
CEOAppio (Thomas J)
Company Executives of Bausch Health Companies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
903.22K
-173.57%
Mr. Jean-Jacques (JJ) Charhon
Mr. Jean-Jacques (JJ) Charhon
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
440.81K
+54.80%
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
164.94K
+84.61%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
107.87K
-0.72%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
6.60K
--
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
5.95K
-38.90%
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mr. John A. Paulson ,
Mr. John A. Paulson ,
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Richard C. Mulligan, Ph.D.
Dr. Richard C. Mulligan, Ph.D.
Independent Director
Independent Director
--
--
Ms. Seana Carson
Ms. Seana Carson
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas J. Appio
Mr. Thomas J. Appio
Chief Executive Officer, Director
Chief Executive Officer, Director
903.22K
-173.57%
Mr. Jean-Jacques (JJ) Charhon
Mr. Jean-Jacques (JJ) Charhon
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
440.81K
+54.80%
Ms. Aimee J. Lenar
Ms. Aimee J. Lenar
Executive Vice President, US Pharma
Executive Vice President, US Pharma
164.94K
+84.61%
Dr. Amy B. Wechsler, M.D.
Dr. Amy B. Wechsler, M.D.
Independent Director
Independent Director
107.87K
-0.72%
Mr. Robert N. Power
Mr. Robert N. Power
Independent Director
Independent Director
6.60K
--
Ms. Sandra Leung
Ms. Sandra Leung
Director
Director
5.95K
-38.90%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Pharmaceutical Products
4.75B
46.24%
Device Products
2.44B
23.76%
OTC
2.01B
19.56%
Branded and Other Generic Products
962.00M
9.37%
Other Product Lines
110.00M
1.07%
By RegionUSD
Name
Revenue
Proportion
United States and Puerto Rico
6.14B
59.79%
Other Foreign Countries
1.15B
11.23%
China (Country)
493.00M
4.80%
Canada
417.00M
4.06%
Poland
382.00M
3.72%
Other
1.68B
16.39%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Pharmaceutical Products
4.75B
46.24%
Device Products
2.44B
23.76%
OTC
2.01B
19.56%
Branded and Other Generic Products
962.00M
9.37%
Other Product Lines
110.00M
1.07%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Paulson (John A.)
19.62%
Paulson & Co. Inc.
19.61%
Meruelo (Alex)
9.84%
GoldenTree Asset Management, LP
9.28%
Nomura Securities Co., Ltd.
2.33%
Other
39.31%
Shareholders
Shareholders
Proportion
Paulson (John A.)
19.62%
Paulson & Co. Inc.
19.61%
Meruelo (Alex)
9.84%
GoldenTree Asset Management, LP
9.28%
Nomura Securities Co., Ltd.
2.33%
Other
39.31%
Shareholder Types
Shareholders
Proportion
Individual Investor
30.54%
Family Office
19.64%
Investment Advisor/Hedge Fund
16.36%
Investment Advisor
9.28%
Hedge Fund
6.87%
Research Firm
4.78%
Bank and Trust
3.82%
Pension Fund
2.84%
Private Equity
1.40%
Other
4.48%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
510
173.34M
46.41%
-64.50M
2025Q4
488
175.10M
70.29%
+43.88K
2025Q3
506
175.09M
71.73%
-42.59M
2025Q2
513
217.71M
72.26%
-4.52M
2025Q1
526
222.33M
72.55%
-45.74M
2024Q4
547
234.63M
78.06%
-1.57M
2024Q3
606
235.66M
83.60%
-25.41M
2024Q2
682
261.12M
90.70%
-4.43M
2024Q1
745
265.27M
94.42%
-80.93M
2023Q4
778
267.72M
94.93%
+4.99M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Paulson & Co. Inc.
73.26M
19.77%
--
--
Dec 31, 2025
Meruelo (Alex)
36.76M
9.92%
+148.73K
+0.41%
Mar 31, 2025
GoldenTree Asset Management, LP
34.67M
9.35%
-167.70K
-0.48%
Dec 31, 2025
Nomura Securities Co., Ltd.
8.70M
2.35%
-7.01M
-44.62%
Dec 31, 2025
Healthcare Of Ontario Pension Plan
8.45M
2.28%
-4.55M
-34.98%
Dec 31, 2025
MFN Partners Management LP
6.00M
1.62%
--
--
Dec 31, 2025
National Bank of Canada
5.32M
1.43%
-2.41M
-31.17%
Dec 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
5.24M
1.41%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
0.3%
Gotham 1000 Value ETF
0.18%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
0.12%
Schwab International Small-Cap Equity ETF
0.09%
iShares Intl Small Cap Equity Factor ETF
0.08%
DFA Dimensional International Small Cap ETF
0.07%
Schwab Fundamental International Equity ETF
0.04%
Invesco RAFI Developed Mkts ex-US ETF
0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
0.01%
iShares Core MSCI International Developed Mkt ETF
0.01%
View more
VanEck Pharmaceutical ETF
Proportion0.3%
Gotham 1000 Value ETF
Proportion0.18%
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index ETF
Proportion0.12%
Schwab International Small-Cap Equity ETF
Proportion0.09%
iShares Intl Small Cap Equity Factor ETF
Proportion0.08%
DFA Dimensional International Small Cap ETF
Proportion0.07%
Schwab Fundamental International Equity ETF
Proportion0.04%
Invesco RAFI Developed Mkts ex-US ETF
Proportion0.03%
DFA Dimensional Intl Sustainability Core 1 ETF
Proportion0.01%
iShares Core MSCI International Developed Mkt ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
